Table 1 SSc-PAH baseline characteristics by sex
From: Sex disparities in systemic sclerosis-associated pulmonary arterial hypertension: a cohort study
SSc patient characteristics | Males | Females | Standardized difference |
|---|---|---|---|
n = 58 | n = 320 | ||
Age at PAH diagnosis, y, mean (SD) | 54.5 (11.0) | 57.3 (13.0) | 0.05 |
Time from SSc to PAH diagnosis, y, mean (SD) | 1.7 (14.0) | 5.5 (14.2) | 0.93a |
PAH disease duration, y, mean (SD) | 3.5 (3.1) | 4.7 (4.2) | 0.29a |
SSc manifestations | |||
Diffuse subtype, n (%) | 23 (40 %) | 69 (22 %) | 0.40a |
Raynaud’s phenomenon, n (%) | 56 (97 %) | 302 (94 %) | 0.10 |
Telangiectasia, n (%) | 46 (79 %) | 224 (70 %) | 0.22 |
Renal crisis, n (%) | 11 (19 %) | 26 (8 %) | 0.32a |
Esophageal dysmotility, n (%) | 51 (88 %) | 276 (86 %) | 0.05 |
Digital ulcers, n (%) | 16 (28 %) | 120 (38 %) | 0.21 |
Interstitial lung disease, n (%) | 39 (67 %) | 153 (48 %) | 0.40a |
ScL-70 antibody, n (%) | 10 (17 %) | 36 (11 %) | 0.17 |
Anticentromere antibody, n (%) | 9 (15 %) | 49 (17 %) | 0.06 |
Cardiopulmonary measures | |||
6MWD, m, mean (SD) | 344.3 (140.9) | 324.5 (154.6) | 0.06 |
WHO functional class III-IV, n (%) | 24 (41 %) | 124 (39 %) | 0.05 |
mPAP, mmHg, mean (SD) | 44.9 (20.5) | 40.7 (21.7) | 0.10 |
mPVR, dyn · s/cm5, mean (SD) | 705.0 (710.5) | 584.7 (552.9) | 0.19 |
Cardiac output L/min, mean (SD) | 4.2 (2.4) | 3.3 (1.6) | 0.26a |
PCWP, mmHg, /mean (SD) | 13.3 (6.2) | 9.5 (6.2) | 0.33a |
BNP pg/mL, mean (SD) | 203.0 (266.9) | 245.9 (481.3) | 0.19 |
FVC, % predicted | 79.3 (17.4) | 76.1 (24.6) | 0.04 |
FEV1, % predicted | 80.3 (18.2) | 78.2 (26.1) | 0.03 |
DLCO, ml/min/mmHg | 52.1 (19.7) | 55.3 (19.5) | 0.06 |
Right ventricular enlargement | |||
Normal | 40 (69 %) | 250 (78 %) | 0.21 |
Mild | 5 (9 %) | 24 (8 %) | 0.04 |
Moderate | 10 (17 %) | 35 (11 %) | 0.18 |
Severe | 3 (5 %) | 11 (3 %) | 0.09 |
Right ventricular dysfunction | |||
Normal | 39 (67 %) | 249 (78 %) | 0.23 |
Mild | 5 (9 %) | 26 (8 %) | 0.02 |
Moderate | 12 (21 %) | 38 (12 %) | 0.24 |
Severe | 2 (3 %) | 7 (2 %) | 0.07 |
Comorbidities | |||
Coronary artery disease, n (%) | 12 (21 %) | 40 (13 %) | 0.22 |
Hypertension, n (%) | 13 (22 %) | 88 (28 %) | 0.12 |
Diabetes mellitus, n (%) | 5 (9 %) | 21 (7 %) | 0.08 |
Hyperlipidemia, n (%) | 8 (14 %) | 26 (8 %) | 0.18 |
Atrial fibrillation, n (%) | 6 (10 %) | 28 (9 %) | 0.05 |
Peripheral vascular disease, n (%) | 3 (5 %) | 19 (6 %) | 0.03 |
Stroke, n (%) | 2 (3 %) | 15 (5 %) | 0.06 |